Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Vera Therapeutics, Inc.

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases that improve patients’ lives.

We’re #hiring! #Joinourteam and take part in our mission to improve the standard of care for patients with serious immunological diseases.
Learn about our open positions here: https://lnkd.in/d2-8KHTC 

Today we announced our Q3 business update and financial results. Read the full release here: https://lnkd.in/df4BxFuY

Dr. Richard Lafayette, MD, FACP, spoke with HCPLive about the additional week 36 analyses from our ORIGIN Phase 2b clinical trial in #IgAN presented at ASN Kidney Week 2023. Watch the interview here: https://lnkd.in/d8eauakC
#kidneywk #IgANephropathy

Today we're presenting two posters with new week 36 analyses from our Phase 2b ORIGIN trial in #IgANephropathy at American Society of Nephrology Kidney Week: https://lnkd.in/dZtKAfQX
Be sure to stop by our posters SA-PO884 and SA-PO887 and visit us at booth 2321! 
#Kidneywk

We’re live at American Society of Nephrology Kidney Week 2023! Come to booth #2321 to learn about our research in #IgANephropathy. And don’t miss our poster presentations on Saturday: https://lnkd.in/dZpvugVK
#kidneywk

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue
gross profit
selling and marketing expenses
general and administrative expenses	4.41M -	4.04M 8.41%	11.92M 195.07%	21.91M 83.84%	23.79M 8.57%
selling general and administrative expenses	4.41M -	4.04M 8.41%	11.92M 195.07%	21.91M 83.84%	23.79M 8.57%
research and development expenses	7.29M -	45.21M 520.11%	22.48M 50.26%	68.99M 206.85%	78.22M 13.38%
other expenses		-1.08M -	1.79M 266.73%	1.85M 3.01%
cost and expenses	11.70M -	49.24M 320.90%	34.40M 30.14%	90.90M 164.24%	102.01M 12.22%
operating expenses	11.70M -	49.24M 320.90%	34.40M 30.14%	90.90M 164.24%	102.01M 12.22%
interest expense	51K -	166K 225.49%	20K 87.95%	992K 4,860%	-3.79M 481.65%
ebitda	-11.03M -	-50.00M 353.22%	-34.40M 31.19%	-90.90M 164.24%	-102.01M 12.22%
operating income	-11.96M -	-52.24M 336.76%	-34.40M 34.15%	-90.90M 164.24%	-102.01M 12.22%
depreciation and amortization	929K -	2.24M 141.33%	176K 92.15%	-846K 580.68%	-2K 99.76%
total other income expenses net	108K -	-1.17M 1,184.26%	1.79M 253.20%	1.85M 3.01%	6.02M 225.92%
income before tax	-11.85M -	-53.41M 350.62%	-32.61M 38.95%	-89.06M 173.11%	-95.99M 7.79%
income tax expense	1K -	1K 0%	1K 0%	1K 0%	-1K 200%
net income	-11.85M -	-53.41M 350.59%	-32.61M 38.95%	-89.06M 173.10%	-95.99M 7.79%
weighted average shs out	4.08M -	4.08M 0%	13.44M 229.60%	26.57M 97.76%	42.71M 60.73%
weighted average shs out dil	4.08M -	4.08M 0%	13.44M 229.60%	26.57M 97.76%	42.71M 60.73%
eps	-2.91 -	-13.10 350.17%	-2.43 81.45%	-3.35 37.86%	-2.25 32.84%
epsdiluted	-2.91 -	-13.10 350.17%	-2.43 81.45%	-3.35 37.86%	-2.25 32.84%

COM:VERATX

Vera Therapeutics, Inc.

Last Close

45.75

21/11 21:00

Market Cap

2.00B

Beta: -

Volume Today

401.03K

Avg: -

Preview